GloboZymes Anti-eIF4E is a rabbit polyclonal antiserum produced against purified preparations of recombinant human kidney eIF4E. It reacts with eIF4E from diverse tissue sources. The antiserum is useful for Western blotting. For example, it is used at 1:500 dilution with 50 μg of bovine liver extracts. The antiserum is also effective for immunoprecipitation.

Synonyms: Polyclonal Antiserum to Eukaryotic Protein Synthesis Initiation Factor 4E; Anti-eIF-4E Polyclonal Antiserum

Background: The mRNA Cap-binding protein eIF4E is involved in an early rate limiting step in the initiation of protein synthesis. In response to growth factors and other extracellular stimuli, eIF4E is phosphorylated at Ser209. This phosphorylation increases the affinity of eIF4E to capped-mRNAs. The Mitogen-Activated Protein Kinase Interacting Kinases (Mnk’s) and an insulin-stimulated cytosolic Protamine Kinase (cPK) phosphorylate eIF4E at Ser209 in cells. In vitro, cPK also phosphorylates eIF4E at Thr210.  eIF4E occurs in cells in an inactive form as a complex with inhibitory binding proteins (4EBP). It also occurs in an active form as part of the eIF4F complex which also contains eIF4A and eIF4G. In response to insulin and other extracellular stimuli, eIF4E is recruited to the eIF4F complex following its dissociation from 4EBP. Over-expression of eIF4E leads to cell transformation and tumorigenesis.

Figure:  Western blot of a purified preparation of recombinant human kidney eIF4E with rabbit Anti-eIF4E Polyclonal Antiserum.

ReferencesJ Biol Chem 270, 14824-14828;  J Biol Chem 270, 14597-14603Biochime 76, 822-830J Biol Chem 271, 11831-11837;  J Biol Chem 270, 21684-21688



Scroll to Top